US 12,409,191 B2
Renal cell populations and uses thereof
Joydeep Basu, Winston-Salem, NC (US); Kelly Guthrie, Winston-Salem, NC (US); Dominic Justewicz, Winston-Salem, NC (US); Teresa Burnette, Winston-Salem, NC (US); Andrew Bruce, Winston-Salem, NC (US); Russell W. Kelley, Winston-Salem, NC (US); and John W. Ludlow, Winston-Salem, NC (US)
Assigned to PROKIDNEY, Grand Cayman (KY)
Filed by ProKidney, Cayman Islands (KY)
Filed on May 26, 2022, as Appl. No. 17/825,652.
Application 17/825,652 is a continuation of application No. 16/459,141, filed on Jul. 1, 2019, granted, now 11,369,639.
Application 16/459,141 is a continuation of application No. 15/623,197, filed on Jun. 14, 2017, granted, now 10,363,274, issued on Jul. 30, 2019.
Application 15/623,197 is a continuation of application No. 14/438,607, abandoned, previously published as PCT/US2013/066707, filed on Oct. 24, 2013.
Claims priority of provisional application 61/876,616, filed on Sep. 11, 2013.
Claims priority of provisional application 61/718,150, filed on Oct. 24, 2012.
Prior Publication US 2022/0347221 A1, Nov. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/22 (2015.01); C12N 5/00 (2006.01); C12N 5/071 (2010.01); G01N 33/569 (2006.01)
CPC A61K 35/22 (2013.01) [C12N 5/0081 (2013.01); C12N 5/0686 (2013.01); G01N 33/56966 (2013.01); C12N 2500/02 (2013.01); C12N 2501/58 (2013.01); C12N 2501/599 (2013.01); G01N 2333/4742 (2013.01); G01N 2333/705 (2013.01); G01N 2333/9108 (2013.01)] 19 Claims
 
1. A method for preparing a formulation for treatment of kidney disease in a mammal comprising:
characterizing a heterogeneous renal cell population prepared from a kidney sample of the mammal as suitable for implantation and/or eliciting a regenerative response, the characterizing comprising:
(i) determining that cells of the population express gamma-glutamyl transpeptidase (GGT)-1;
(ii) determining that cells of the population express a cytokine cytokeratin (CK); and
(iii) determining that cells of the population secrete vascular endothelial growth factor (VEGF) and kidney injury molecule (KIM)-1; and
formulating the heterogeneous renal cell population, characterized as suitable for implantation and/or eliciting the regenerative response, with a (i) biomaterial or (ii) pharmaceutically acceptable carrier or excipient.